Pharvaris NV
NASDAQ:PHVS
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Kantone Holdings Ltd
HKEX:1059
|
HK |
|
K
|
Kalmar Oyj
OMXH:KALMAR
|
FI |
|
iEnergizer Ltd
LSE:IBPO
|
GG |
|
MSM International Ltd
SGX:5QR
|
MY |
|
S
|
Sichuan Baicha Baidao Industrial Co Ltd
HKEX:2555
|
CN |
|
C
|
Chutian Dragon Co Ltd
SZSE:003040
|
CN |
|
Wuhan Zhongyuan Huadian Science & Technology Co Ltd
SZSE:300018
|
CN |
|
Aditya Birla Capital Ltd
NSE:ABCAPITAL
|
IN |
EV/EBIT
Enterprise Value to EBIT (EV/EBIT) ratio compares a company`s total enterprise value to its earnings before interest and taxes. It shows how much investors are paying for each dollar of the company`s earnings, including both equity and debt.
Enterprise Value to EBIT (EV/EBIT) ratio compares a company`s total enterprise value to its earnings before interest and taxes. It shows how much investors are paying for each dollar of the company`s earnings, including both equity and debt.
Valuation Scenarios
If EV/EBIT returns to its Country Average (15.6), the stock would be worth $-57.05 (297% downside from current price).
| Scenario | EV/EBIT Value | Implied Price | Upside/Downside |
|---|---|---|---|
| Current Multiple | -7.9 | $28.97 |
0%
|
| Country Average | 15.6 | $-57.05 |
-297%
|
Forward EV/EBIT
Today’s price vs future ebit
Peer Comparison
| Market Cap | EV/EBIT | P/E | ||||
|---|---|---|---|---|---|---|
| NL |
|
Pharvaris NV
NASDAQ:PHVS
|
1.9B USD | -7.9 | -9.3 | |
| US |
|
Eli Lilly and Co
NYSE:LLY
|
869.1B USD | 30.4 | 42.1 | |
| US |
|
Johnson & Johnson
NYSE:JNJ
|
555.5B USD | 21.7 | 26.4 | |
| CH |
|
Roche Holding AG
SIX:ROG
|
248.4B CHF | 13.2 | 19.8 | |
| UK |
|
AstraZeneca PLC
LSE:AZN
|
231.9B GBP | 23.4 | 30 | |
| US |
|
Merck & Co Inc
NYSE:MRK
|
289.8B USD | 12 | 15.9 | |
| CH |
|
Novartis AG
SIX:NOVN
|
228B CHF | 16.1 | 20.3 | |
| IE |
E
|
Endo International PLC
LSE:0Y5F
|
244.4B USD | 970 | -83.6 | |
| DK |
|
Novo Nordisk A/S
CSE:NOVO B
|
1.2T DKK | 9.6 | 11.2 | |
| US |
|
Pfizer Inc
NYSE:PFE
|
156.5B USD | 10.3 | 20.1 | |
| US |
|
Bristol-Myers Squibb Co
NYSE:BMY
|
119B USD | 8.8 | 16.9 |
Market Distribution
| Min | 0 |
| 30th Percentile | 12.2 |
| Median | 15.6 |
| 70th Percentile | 20.9 |
| Max | 706 |
Other Multiples
Pharvaris NV
Glance View
Pharvaris NV is a clinical-stage biopharmaceutical company. The company is headquartered in Leiden, Zuid-Holland and currently employs 34 full-time employees. The activity of the Company focuses on producing oral bradykinin B2-receptor antagonists and is advancing new alternatives to injected therapies for all sub-types of hereditary angioedema (HAE).
